[Evaluation of the effectiveness of Quinax in the prevention of the development of senile cataract].
The authors evaluated the efficacy of Quinax in 4 groups of patients with cataract. An observation of--on the average--5 years duration showed that systematic application of the drug prevents the development of the early senile cataract and distinctly slows down the progress of the disease in the group of patients without the risk factors. Non systematic application of the compound also slows down the progress of the condition in the group of early cataract. The drug was ineffective in patients with an advanced diabetic cataract.
Stankiewicz
A
A
Z Kliniki Okulistycznej AM w Białymstoku.
Poppe
E
E
Stasiewicz
B
B
Gołebiowska-Hrycukowa
A
A
D000166:Acridines / Q000008:administration & dosage*; D000368:Aged; D002386:Cataract / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D006801:Humans; D007908:Lens, Crystalline / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D014792:Visual Acuity / Q000187:drug effects / Q000502:physiology
D000166:Acridines; D009883:Ophthalmic Solutions; C027197:phacolysin
Ocena skuteczności Quinaxu w zapobieganiu rozwojowi zaćmy starczej.